Left ventricular myxoma presenting with constitutional symptoms and raised serum interleukin-6 both suppressed by naproxen

Vaughan, Carl J.; Gallagher, M.; Murphy, Michael B.

doi:10.1093/oxfordjournals.eurheartj.a015326

Cited by 7 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specific recent examples of this: naproxen clinically reduced IL-6 in IL-6-overproducing pheochromocytoma [ 167 ], in sera of patient with osteoarthritis [ 168 ], in subchondral osteoartrthritis osteoblasts [ 169 ], and in osteoarthritis patient synovial cells ex vivo [ 170 ]. Also in rheumatoid arthritis plasma and synovial fluid show increased IL-6 that is decreased by naproxen treatment [ 171 ]], and in a cardiac myxoma patient with elevated IL-6 [ 172 ]. In accord with what we know of intracellular control of IL-6 generation, COX inhibition generally reduces circulating IL-6.…”

Section: The Eis Regimen: Emt Triggers Maintenance Factors and 6 Cumentioning

confidence: 99%

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen

Kast¹,

Skuli

Karpel‐Massler

et al. 2017

Oncotarget

View full text Add to dashboard Cite

This paper outlines a treatment protocol to run alongside of standard current treatment of glioblastoma- resection, temozolomide and radiation. The epithelial to mesenchymal transition (EMT) inhibiting sextet, EIS Regimen, uses the ancillary attributes of six older medicines to impede EMT during glioblastoma. EMT is an actively motile, therapy-resisting, low proliferation, transient state that is an integral feature of cancers’ lethality generally and of glioblastoma specifically. It is believed to be during the EMT state that glioblastoma’s centrifugal migration occurs. EMT is also a feature of untreated glioblastoma but is enhanced by chemotherapy, by radiation and by surgical trauma. EIS Regimen uses the antifungal drug itraconazole to block Hedgehog signaling, the antidiabetes drug metformin to block AMP kinase (AMPK), the analgesic drug naproxen to block Rac1, the anti-fibrosis drug pirfenidone to block transforming growth factor-beta (TGF-beta), the psychiatric drug quetiapine to block receptor activator NFkB ligand (RANKL) and the antibiotic rifampin to block Wnt- all by their previously established ancillary attributes. All these systems have been identified as triggers of EMT and worthy targets to inhibit. The EIS Regimen drugs have a good safety profile when used individually. They are not expected to have any new side effects when combined. Further studies of the EIS Regimen are needed.

show abstract

Section: The Eis Regimen: Emt Triggers Maintenance Factors and 6 Cumentioning

confidence: 99%

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen

Kast¹,

Skuli

Karpel‐Massler

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

Tumors of the Heart

Stainback

Hamirani

Cooley³

et al. 2007

Cardiovascular Medicine

View full text Add to dashboard Cite

Melanoma inhibition by cyclooxygenase inhibitors

Kast

2007

Med Oncol

View full text Add to dashboard Cite

Melanoma progression is often associated with supranormal levels of interleukin-6 (IL-6). Il-6 is an important growth factor for many cases of melanoma. A recent case report by Lejeune et al. [Melanoma Res 2006;16:263-265] of remission of an advanced melanoma during treatment with the cyclooxygenase, (COX) inhibitor rofecoxib can be explained by rofcoxib-mediated lowering of tumor-produced Il-6. Several examples of rofecoxib's ability to lower Il-6 in humans have been published recently in other settings, and many reports indicate that other commonly used COX inhibitors like aspirin, diclofenac, etodolac, indomethacin, naproxen, and many others, also lower Il-6 in humans. These studies are reviewed. The likely mechanism of COX inhibition leading to Il-6 lowering is due to the tendency for Il-6 levels to be controlled by intracellular cyclic adenosine monophosphate (cAMP). Adenylate cyclase is the rate-limiting enzyme in cAMP synthesis. Because adenylate cyclase activity is allosterically enhanced when it binds prostaglandin E, the latter increases Il-6. COX inhibition lowers prostaglandin E levels. This lowers intracellular cAMP levels. Lower cAMP results in lower Il-6 synthesis, lower levels of a required growth factor. Controlled studies are needed to define the role of COX inhibitors in melanoma treatment.

show abstract

Left ventricular myxoma presenting with constitutional symptoms and raised serum interleukin-6 both suppressed by naproxen

Cited by 7 publications

References 0 publications

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen

Tumors of the Heart

Melanoma inhibition by cyclooxygenase inhibitors

Contact Info

Product

Resources

About